10:32 AM EST, 01/26/2026 (MT Newswires) -- Mirum Pharmaceuticals ( MIRM ) said Monday it has completed the acquisition of Bluejay Therapeutics and closed private placements worth $268.5 million.

Under the terms of the deal announced in December, Mirum agreed to acquire Bluejay for $250 million in cash and $370 million in shares, along with potential milestone payments of up to $200 million.

Mirum said it now has global rights to brelovitug, a potential treatment for chronic hepatitis delta virus, which is currently being evaluated in the Azure phase 3 registrational program, with topline data expected in H2.

Funds from the private placements will be used to support clinical development and commercial activities after the acquisition of brelovitug, the company said, adding it will assess options for Bluejay's additional investigational programs.

Shares of Mirum were up 1.9% in recent Monday trading.

Price: 96.08, Change: +1.79, Percent Change: +1.90